Heritable Resistance to Tyrosine Kinase Inhibitors

July 2014, Volume 12, Issue 7 S. Tiong Ong, MA, MRCP Associate Professor, Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School Singapore and Department of Medicine, Duke […]

Mining the Internet for Drug Information

Clinical Advances in Hematology & Oncology June 2014, Volume 12, Issue 6 Nigam Shah, MBBS, PhD, Assistant Professor of Medicine, Stanford University School of Medicine, Stanford, California H&O How did […]

Clinical Trial Design for Phase 1 Studies of Drug Combinations

Clinical Advances in Hematology & Oncology May 2014, Volume 12, Issue 5 Channing Paller, MD Assistant Professor of Oncology Johns Hopkins University Baltimore, Maryland Member, Clinical […]

Clinical Implementation of Next-Generation Sequencing

Clinical Advances in Hematology & Oncology April 2014, Volume 12, Issue 4 Richard D. Press, MD, PhD Director of Molecular Pathology, Department of Pathology & Knight Cancer Institute, Oregon […]

Genetic Engineering of T Cells in Leukemia and Lymphoma

Clinical Advances in Hematology & Oncology March 2014, Volume 12, Issue 3 James N. Kochenderfer, MD Investigator, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland H&O How does chimeric […]

Biomarkers in Castration-Resistant Prostate Cancer

Clinical Advances in Hematology & Oncology February 2014, Volume 12, Issue 2 Biomarkers in Castration-Resistant Prostate Cancer Andrew J. Armstrong, MD, Associate Professor of Medicine and Surgery, Duke […]

New Drugs and Treatment Strategies in Prostate Cancer

Clinical Advances in Hematology & Oncology January 2014, Volume 12, Issue 1 Matthew D. Galsky, MD Associate Professor of Medicine, Hematology, and Medical Oncology Icahn School of […]

Neoadjuvant Pertuzumab in Early HER2-Positive Breast Cancer

Clinical Advances in Hematology & Oncology December 2013, Volume 11, Issue 12 Neoadjuvant Pertuzumab in Early HER2-Positive Breast Cancer Mikkael A. Sekeres, MD, MS , Director, Leukemia Program, Professor […]

Update on Ibrutinib

Clinical Advances in Hematology & Oncology November 2013, Volume 11, Issue 11 Update on Ibrutinib Susan M. O’Brien, MD, Ashbel Smith Professor, Department of Leukemia, Division of Cancer Medicine, UT MD […]

New Drugs for Gastrointestinal Stromal Tumors

Clinical Advances in Hematology & Oncology October 2013, Volume 11, Issue 10 Christopher Garrett, MD Associate Professor Department of Gastrointestinal Medical Oncology Division of Cancer Medicine The […]

Metformin’s Potential in Oncology

Clinical Advances in Hematology & Oncology September 2013, Volume 11, Issue 9 Michael Pollak, MD Alexander Goldfarb Research Chair and Professor, Department of Oncology, Department of Medicine, McGill […]

Unmet Needs in Preventing Adverse Drug-Drug Interactions

Clinical Advances in Hematology & Oncology August 2013, Volume 11, Issue 8 Mark J. Ratain, MD Leon O. Jacobson Professor of Medicine, Director, Center for Personalized […]

Potential Anticancer Benefits of Peptide Vaccines

Clinical Advances in Hematology & Oncology July 2013, Volume 11, Issue 7 Yusuke Nakamura, MD, PhD Professor of Medicine, Section of Hematology/Oncology, Professor of Surgery, Deputy Director, Center for […]

New Targets for Hematologic Malignancies

Clinical Advances in Hematology & Oncology June 2013, Volume 11, Issue 6 James Bradner, MD Assistant Professor, Department of Medicine, Harvard Medical School, Instructor in Medicine, Hematologic Neoplasia/Malignancies, Dana-Farber Cancer […]

Accounting for Tumor Heterogeneity in the Development of Predictive Biomarkers

Clinical Advances in Hematology & Oncology May 2013, Volume 11, Issue 5 Lillian L. Siu, MD, FRCPC Professor, University of Toronto, Cancer Care Ontario Research Chair, Experimental Therapeutics, Medical […]

Developing Drugs for Pediatric Malignancies

Clinical Advances in Hematology & Oncology April 2013, Volume 11, Issue 4 Peter C. Adamson, MD Chair, Children’s Oncology Group, Chief, Division of Clinical Pharmacology & Therapeutics, The […]

Update on CYP2D6 and Tamoxifen

Clinical Advances in Hematology & Oncology March 2013, Volume 11, Issue 3 Matthew P. Goetz, MD Consultant, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota H&O What […]

Generic Sirolimus: A Future Opportunity to Decrease the Cost of Oncology Care?

Clinical Advances in Hematology & Oncology February 2013, Volume 11, Issue 2 Laurence H. Baker, DO Collegiate Professor, Cancer Developmental Therapeutics, Professor, Internal Medicine and Pharmacology, University of […]

Tivozanib in Renal Cell Carcinoma

Robert Figlin, MD, FACP Steven Spielberg Family Chair in Hematology-Oncology, Professor of Medicine and Biomedical Sciences, Chair, Division of Hematology Oncology, Deputy Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los […]

ROS1-Targeted Therapy in Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology December 2012, Volume 10, Issue 12 H&O What is ROS1, and what is its mechanism of action? LS ROS1 is […]